三阴性对小肿块乳腺癌患者预后的影响

刘晓东 汪旭 贾勇圣 王蕊 佟仲生

刘晓东, 汪旭, 贾勇圣, 王蕊, 佟仲生. 三阴性对小肿块乳腺癌患者预后的影响[J]. 中国肿瘤临床, 2012, 39(9): 578-582. doi: 10.3969/j.issn.1000-8179.2012.09.023
引用本文: 刘晓东, 汪旭, 贾勇圣, 王蕊, 佟仲生. 三阴性对小肿块乳腺癌患者预后的影响[J]. 中国肿瘤临床, 2012, 39(9): 578-582. doi: 10.3969/j.issn.1000-8179.2012.09.023
Xiaodong LIU, Xu WANG, Yongsheng JIA, Rui WANG, Zhongsheng TONG. Clinicopathologic Features and Prognosis of T1a and T1b Triple-Negative Breast Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(9): 578-582. doi: 10.3969/j.issn.1000-8179.2012.09.023
Citation: Xiaodong LIU, Xu WANG, Yongsheng JIA, Rui WANG, Zhongsheng TONG. Clinicopathologic Features and Prognosis of T1a and T1b Triple-Negative Breast Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(9): 578-582. doi: 10.3969/j.issn.1000-8179.2012.09.023

三阴性对小肿块乳腺癌患者预后的影响

doi: 10.3969/j.issn.1000-8179.2012.09.023
基金项目: 

天津市应用基础及前沿技术研究计划 10JCYBJC11500

详细信息
    通讯作者:

    佟仲生  tonghang@medmail.com.cn

Clinicopathologic Features and Prognosis of T1a and T1b Triple-Negative Breast Cancer

More Information
  • 摘要:   目的  分析小肿块(直径≤1 cm)乳腺癌患者的临床及病理学特征,了解其生存状态,探讨三阴性对其预后的影响。  方法  收集本院收治的312例直径≤1 cm乳腺癌患者的临床病理学资料,比较三阴性乳腺癌及非三阴性乳腺癌的临床病理学特征、复发转移及生存情况。  结果  312例直径≤1 cm乳腺癌患者纳入研究,三阴组及非三阴组5年DFS分别为81.4%及90.5%(P= 0.038),5年BCSS分别为84.7%及93.7%(P=0.047)。以淋巴结状态分组比较,淋巴结阴性患者中,三阴组及非三阴组5年DFS分别为82.8%及94.1%(P=0.033),5年BCSS分别为85.0%及96.1%(P=0.019)。Cox比例风险模型多因素分析显示,淋巴结阳性患者复发转移风险增高(HR=3.721,95%CI:1.743~7.941,P=0.001),死亡风险亦增高(HR=3.560,95%CI:1.521~8.330,P=0.003),三阴性患者复发转移风险增高(HR=2.208,95%CI:1.028~4.742,P=0.042)。  结论  淋巴结阳性及三阴性是影响直径≤1 cm乳腺癌患者DFS的独立危险因素,淋巴结阳性是影响BCSS的唯一独立危险因素。淋巴结阴性三阴性乳腺癌组较非三阴组预后差。

     

  • 图  1  直径≤1 cm乳腺癌患者各组别DFS及BCSS比较

    A:三阴性与非三阴性乳腺癌DFS比较;B:三阴性与非三阴性乳腺癌BCSS比较;C:淋巴结阴性三阴性与非三阴性乳腺癌DFS比较;D:淋巴结阴性三阴性与非三阴性乳腺癌BCSS比较

    Figure  1.  Comparison of DFS and BCSS among groups with breast cancer size ≤1 cm

    表  1  三阴性与非三阴性直径≤1 cm乳腺癌患者的临床病理特征比较

    Table  1.   Comparison of clinicopathological features between TNBC and non-TNBC patients with tumor size ≤1 cm

    表  2  影响DFS及BCSS的Cox比例风险回归单因素及多因素分析

    Table  2.   Univariate and multivariate Cox regression analysis for DFS and BCSS

    表  3  不同组别乳腺癌患者化疗比率、5年DFS及BCSS比较

    Table  3.   Proportion of chemotherapy, 5-year DFS, and BCSS in patients of different groups

  • [1] Benson JR, Jatoi I, Keisch M, et al. Early breast cancer[J]. Lancet, 2009, 373: 1463-1479. doi: 10.1016/S0140-6736(09)60316-0
    [2] Dent R, Trudeau M, Pritchard KI, et al. Triple- negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13: 4429-4434. doi: 10.1158/1078-0432.CCR-06-3045
    [3] Sánchez-Muñoz A, Pérez-Ruiz E, Jurado JM. Outcome of small invasive breast cancer with no axillary lymph node involvement[J]. Breast J. 2011, 17(1): 32-38. doi: 10.1111/j.1524-4741.2010.01026.x
    [4] Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options[J]. Lancet Oncol, 2007, 8(3): 235-244. doi: 10.1016/S1470-2045(07)70074-8
    [5] Smart CR, Byrne C, Smith RA, et al. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project[J]. CA Cancer J Clin, 1997, 47(3): 134-149. doi: 10.3322/canjclin.47.3.134
    [6] Chen YY, Schnitt SJ. Prognostic factors for patients with breast cancers 1cm and smaller[J]. Breast Cancer Res Treat, 1998, 51(3): 209-225. doi: 10.1023/A:1006130911110
    [7] Leitner SP, Swern AS, Weinberger D, et al. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a, bN0M0)[J]. Cancer, 1995, 76: 2266-2274. doi: 10.1002/1097-0142(19951201)76:11<2266::AID-CNCR2820761114>3.0.CO;2-T
    [8] Kwon JH, Kim YJ, Lee KW, et al. Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less[J]. BMC Cancer, 2010, 10: 557-564. doi: 10.1186/1471-2407-10-557
    [9] Park YH, Kim ST, Cho EY, et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment[J]? Breast Cancer Res Treat, 2010, 119(3): 653-661. doi: 10.1007/s10549-009-0665-x
    [10] Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes[J]. Breast Cancer Res Treat, 2011, 127(3): 713-720. doi: 10.1007/s10549-011-1465-7
    [11] Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies[J]. J Clin Oncol, 2004, 22: 1630-1637. doi: 10.1200/JCO.2004.09.070
    [12] Hassett MJ, Hughes ME, Niland JC, et al. Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer[J]. J Clin Oncol, 2008, 26(34): 5553-5560. doi: 10.1200/JCO.2008.17.9705
    [13] Elder EE, Hay SB, Moore K. Factors Influencing Treatment Recommendations in Node-Negative Breast Cancer[J]. J Oncol Pract, 2011, 7(1): 26-30. doi: 10.1200/JOP.2010.000024
    [14] Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J]. Ann Oncol, 2009, 20 (8): 1319-1329. doi: 10.1093/annonc/mdp322
  • 加载中
图(1) / 表(3)
计量
  • 文章访问数:  64
  • HTML全文浏览量:  3
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-10-06
  • 修回日期:  2012-03-21

目录

    /

    返回文章
    返回